Korea Exchange · Healthcare
Yuhan stock from India: price, numbers and tax
Yuhan (000100) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Yuhan at a glance
- Price
- ₩73,100.00-₩1,900.00 (2.53%)
- Market cap
- ₩5.38T
- Day range
- ₩73,100.00 – ₩74,700.00
- P/E
- 25.57
- Dividend yield
- 0.82%
- Volume
- 357.74K
- 1 month
- -7.35%
- 6 months
- -21.31%
- YTD
- -34.96%
- 1 year
- -39.44%
- 5 years
- +42.22%
Yuhan statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩2.2T | ₩2.1T | ₩1.9T | ₩1.8T | ₩1.7T |
| Gross profit | ₩728.5B | ₩689.4B | ₩564.5B | ₩518.2B | ₩524.7B |
| Operating income | ₩123.6B | ₩54.9B | ₩74.6B | ₩36.0B | ₩48.6B |
| Net income | ₩194.1B | ₩70.7B | ₩136.2B | ₩95.1B | ₩102.6B |
| Earnings per share | ₩2,599.00 | ₩943.00 | ₩1,816.00 | ₩1,206.67 | ₩1,357.03 |
| EBITDA | ₩174.5B | ₩139.2B | ₩127.4B | ₩78.1B | ₩123.9B |
| Total assets | ₩3.3T | ₩2.9T | ₩2.8T | ₩2.5T | ₩2.5T |
| Total debt | ₩343.2B | ₩303.0B | ₩230.1B | ₩95.4B | ₩124.8B |
| Cash and short-term investments | ₩378.1B | ₩330.7B | ₩322.0B | ₩347.7B | ₩430.5B |
| Shareholders' equity | ₩2.3T | ₩2.1T | ₩2.0T | ₩2.0T | ₩1.9T |
| Operating cash flow | ₩106.2B | ₩54.6B | ₩144.1B | ₩99.5B | ₩99.0B |
| Free cash flow | −₩3.6B | −₩79.3B | −₩59.9B | ₩5.2B | ₩17.1B |
| Capital expenditure | −₩109.9B | −₩133.9B | −₩204.1B | −₩94.4B | −₩81.9B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Daewoong pharmaceutical | 069620.KS | ₩108,500.00 | ₩1.25T |
| JW Pharmaceutical | 001060.KS | ₩26,350.00 | ₩608.52B |
| Ildong Pharmaceutical | 249420.KS | ₩14,020.00 | ₩441.74B |
| Bukwang Pharmaceutical | 003000.KS | ₩4,055.00 | ₩400.09B |
| Hyundai Pharmaceutical | 004310.KS | ₩7,760.00 | ₩181.97B |
| Daihan Pharmaceutical | 023910.KQ | ₩25,850.00 | ₩152.00B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| Ilyang Pharmaceutical | 007570.KS | ₩7,950.00 | ₩142.50B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Yuhan from India
What Yuhan does
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Yuhan operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Yuhan shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.